BioVie/BIVI

$1.27

3.25%
-
1D1W1MYTD1YMAX

About BioVie

BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Ticker

BIVI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Cuong Do

Employees

18

Headquarters

Carson city, United States

BioVie Metrics

BasicAdvanced
$49.04M
Market cap
-
P/E ratio
-$1.19
EPS
1.33
Beta
-
Dividend rate

What the Analysts think about BioVie

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analysts.
766.14% upside
High $11.00
Low $11.00
$1.27
Current price
$11.00
Average price target

BioVie Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
-
Net income
$-8.4M
-21.5%
Profit margin
0%
-

BioVie Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 30.6%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.43
-$0.25
-$0.29
-$0.22
-
Expected
-$0.36
-$0.40
-$0.31
-$0.32
-$0.33
Surprise
21.13%
-37.34%
-6.45%
-30.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell BioVie stock

Buy or sell BioVie stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing